Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dystrophin mRNA is a large (~14 kb) mature messenger RNA transcribed from the human *DMD* gene located on chromosome Xp21. It serves as the template for synthesis of full-length and various shorter isoforms of the cytoskeletal protein **dystrophin**, which plays an essential role in stabilizing muscle cell membranes by linking cytoskeletal actin filaments to extracellular matrix components via associated glycoproteins. Mutations affecting either transcription, processing, or translation lead directly to severe neuromuscular diseases such as Duchenne muscular dystrophy. Therapeutic strategies have been developed that specifically target aberrant *DMD* pre-mRNAs using antisense oligonucleotides—these drugs bind specific exons within precursor transcripts and promote their exclusion during splicing ("exon skipping"), thereby restoring partial function even when frameshift mutations are present.
Drugs targeting this molecule generally act by: Binding specific sequences on pre-messenger RNA to modify splicing patterns and restore an open reading frame, enabling production of partially functional truncated proteins in patients with certain mutations.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophin mRNA.